Symphogen seeks partner to complete development of drug candidate  

2008.07.17
Danish biotech company Symphogen is looking for a partner to help complete the development of its drug candidate for the treatment of Respiratory Syncytial Virus
Danish biotech company Symphogen is looking for a partner to help complete the development of its drug candidate for the treatment of Respiratory Syncytial Virus (RSV), which is a common cause of acute bronchitis in small children during the winter months. Symphogen entered a global strategic collaboration a month ago with USA's Genentech for antibody therapeutics against infectious disease targets, a deal worth a potential USD 330m to Symphogen.
 
Symphogen MD Kirsten Drejer told financial daily newspaper Børsen: "We have reached a point in the development where we need a partner. We are not able ourselves to carry out large clinical studies on more than 1,000 people. So we are focusing on finding a partner who can help us to progress the drug."
 
RSV is the most frequent cause of serious respiratory tract infections in small children. The virus poses a critical risk in babies who are born prematurely. There is no treatment for the disease, but prematurely born babies receive prophylactic treatment, typically with a drug that contains a single antibody. Symphogen has developed a drug with two antibodies, and tests in mice indicate that it is more effective than the existing drug with one antibody. If things go according to plan, the new drug could be marketed in 2014.
 
Based in Copenhagen, Symphogen develops therapeutic products based on recombinant polyclonal antibodies that capture the diversity and effectiveness of the natural immune system. Symphogen's product pipeline covers several disease areas including infectious diseases and cancer.
 
Link > Symphogen    

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×